Clinical Trial Update: Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating presurgical bortezomib followed by postoperative bortezomib and temozolomide for recurrent malignant gliomas; results were posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Temodar (Temozolomide)
• Velcade (bortezomib)

Snippet

Sponsor: Northwestern University | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED | Results posted: 2014-01-13